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Objective: Brain-derived neurotrophic factor (BDNF) levels are decreased in individuals
with depression and increase following antidepressant treatment. The objective of this
study is to compare pre- and post-treatment serum BDNF levels in patients with drug-
resistant major depressive disorder (MDD) who received either electroconvulsive ther-
apy (ECT) or repetitive transcranial magnetic stimulation (rTMS). It is hypothesized that
non-pharmacological treatments also increase serum BDNF levels. Methods: This was a
prospective, single-blind study comparing pre- and post-treatment serum BDNF levels of
29 patients with drug-resistant MDD who received ECT or rTMS treatment. Serum BDNF
levels were measured 1week prior to and 1week after treatment using the sandwich
ELISA technique. Depression severity wasmeasured 1week before and 1week after treat-
ment using the Hamilton Depression Rating Scale. Two-sided normal distribution paired
t -test analysis was used to compare pre- and post-treatment BDNF concentration and ill-
ness severity. Bivariate correlations using Pearson’s coefﬁcient assessed the relationship
between post-treatment BDNF levels and post-treatment depression severity. Results
There was no signiﬁcant difference in serum BDNF levels before and after ECT, although
concentrations tended to increase from a baseline mean of 9.95–12.29 ng/ml after treat-
ment (p = 0.137). Treatment with rTMS did not signiﬁcantly alter BDNF concentrations
(p = 0.282). Depression severity signiﬁcantly decreased following both ECT (p = 0.003)
and rTMS (p< 0.001). Post-treatment BDNF concentration was not signiﬁcantly correlated
with post-treatment depression severity in patients who received either ECT (r =−0.133,
p = 0.697) or rTMS (r = 0.374, p = 0.126). It is important to note that these results are based
on the small number of patients included in this study. Conclusion: This study suggests
that ECT and rTMS may not exert their clinical effects by altering serum BDNF levels in
patients with drug-resistant MDD. Serum BDNF concentration may not be a biomarker of
ECT or rTMS treatment response.
:
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INTRODUCTION
Depression is associated with neuronal atrophy and cell loss in dis-
crete regions of the brain, including the prefrontal cortex and the
hippocampus (Sapolsky, 1996; Sheline et al., 1996; Sheline et al.,
1999; Bremner et al., 2000; Warner-Schmidt and Duman, 2006).
Neurotrophins have a crucial role in brain development, survival
and maintenance of neuronal functions, and synaptic plasticity
(Kaplan and Miller, 2000). The neurotrophin brain-derived neu-
rotrophic factor (BDNF) promotes the survival of central nervous
system (CNS) neurons including hippocampal, cortical, cholin-
ergic, nigral dopaminergic, and serotonergic neurons (Alderson
et al., 1990; Hyman et al., 1991; Ghosh et al., 1994; Eaton and
Whittemore, 1996; Lindholm et al., 1996). Recent research sug-
gests that BDNF is involved in the pathophysiology of depression
as well as in the mechanism of action of antidepressant treatments
(Hashimoto et al., 2004;Angelucci et al., 2005;Russo-Neustadt and
Chen, 2005; Schmidt and Duman, 2010). Serum BDNF levels in
antidepressant-naive individuals suffering from major depressive
disorder (MDD) tend to be signiﬁcantly lower than BDNF lev-
els in both individuals treated for depression and healthy controls
(Karege et al., 2002a, 2005; Shimizu et al., 2003; Lee et al., 2007; Sen
et al., 2008; Bocchio-Chiavetto et al., 2010). Furthermore, BDNF
levels are negatively correlated with depression severity.
Pharmacological treatments have been shown to effect serum
BDNF levels. While BDNF levels are lower in depressed patients,
serum BDNF levels of depressed patients increase after treat-
ment with antidepressants or mood stabilizers (Chen et al., 2001;
Shimizu et al., 2003; Aydemir et al., 2005; Gervasoni et al., 2005;
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Gonul et al., 2005; Huang et al., 2007; Yoshimura et al., 2007;
Brunoni et al., 2008; Hellweg et al., 2008; Monteleone et al., 2008;
Piccinni et al., 2008; Sen et al., 2008; Matrisciano et al., 2009). A
recent meta-analysis showed that changes in BDNF levels are sig-
niﬁcantly correlated with changes in depression severity (Brunoni
et al., 2008). The antidepressants sertraline, amitriptyline, parox-
etine, and ﬂuoxetine have been particularly successful in raising
BDNF levels in patients suffering from MDD (Hashimoto et al.,
2004; Aydemir et al., 2005; Yoshimura et al., 2007; Matrisciano
et al., 2009).
The effect of non-pharmacological treatments for MDD on
serum BDNF levels is conﬂicting and remains to be established.
Both electroconvulsive therapy (ECT) and repetitive transcra-
nial magnetic stimulation (rTMS) are effective in the treatment
of MDD and are becoming more widely used as alternatives to
pharmacological treatments in drug-resistant patients (Hoffman
and Cavus, 2002; Tamminga et al., 2002; Gershon et al., 2003;
Schlaepfer et al., 2003; Lisanby, 2007). Researchers have recently
investigated the effect of ECT and rTMS on serum BDNF levels.
Some studies have shown that ECT increases serum BDNF lev-
els in animals (Angelucci et al., 2002; Altar et al., 2003; Sartorius
et al., 2009), as well as in patients with treatment-resistant MDD
(Bocchio-Chiavetto et al., 2006; Marano et al., 2007; Okamoto
et al., 2008; Hu et al., 2010). Some studies, however, have not been
able to replicate this ﬁnding (Fernandes et al., 2009; Gronli et al.,
2009). Similarly, studies have reported that rTMS increases serum
BDNF levels (Yukimasa et al., 2006; Zanardini et al., 2006), while
another found that rTMS did not alter serum BDNF levels in
patients with MDD (Lang et al., 2006). Therefore, further research
is needed to determine the effect of ECT and rTMSonBDNF levels
in depressed patients.
The primary objective of this study is to examine the effect of
ECT and rTMS on serum BDNF levels in patients with treatment-
resistant MDD. Secondly, the correlation between serum BDNF
level and illness severity will be assessed. We hypothesize that ECT
and rTMS will increase serum BDNF levels, inducing a neuro-
protective effect, which contributes to decreased illness severity.
A correlation between the change in BDNF levels and change in
symptom severity may suggest that BDNF has a central role in the
molecularmechanismof actionof ECTand rTMS treatments. Fur-
thermore, such a ﬁnding would support BDNF as a biochemical
marker of MDD.
MATERIALS AND METHODS
STUDY DESIGN
This was a prospective, single-blind study comparing pre- and
post-treatment serum BDNF levels of patients with treatment-
resistant MDD who were currently experiencing a major depres-
sive episode and received ECT or rTMS treatment. Patients were
recruited from a single-center, tertiary care mood disorders clinic.
The study was approved by the Queen’s University Health Sciences
and Afﬁliated Teaching Hospitals Research Ethics Boards.
STUDY POPULATION
Patients were recruited from inpatient and outpatient services for
the evaluation and treatment of depression. All participants were
18 years of age or older and gave written informed consent. All
patients had a Diagnostic and Statistical Manual of Mental Disor-
ders, 4th edition (DSM-IV) diagnosis of MDD, and were currently
experiencing a major depressive episode [Hamilton Depression
Rating Scale-17 item (HDRS-17) ≥ 15, Young Mania Rating Scale
(YMRS)≤ 8]. Participants with anorexia nervosa, bulimia ner-
vosa, a previous diagnosis of schizophrenia, and/or current sub-
stance abuse (except caffeine and nicotine) were excluded. Patients
who received either ECT or rTMS within the year prior to entry
into the study were excluded. Patients with any other primary
psychiatric diagnosis, an uncontrolled medical illness, a severe
personality disorder, epilepsy, or any medical illness thought to
affect serum levels of BDNF were also excluded from the study.
Changes to baseline medication regimes were not allowed in the 3-
weeks prior to participationor during the study. Studyparticipants
were withdrawn from the study if they experienced signiﬁcant side
effects, became pregnant or withdrew consent.
Thirty-one patients were originally enrolled in the trial; how-
ever two patients (one in ECT group and one in rTMS group)
were excluded due to signiﬁcant changes in medication over the
course of the study. This left 29 patients remaining in the study.
Eleven patients received ECT and 18 patients received rTMS. The
ECT population consisted of four men and seven women, with
a mean age of 46.5 years. The rTMS population consisted of 5
men and 13 women, with a mean age of 44.7 years. Twenty-two
of 29 patients were taking antidepressants (escitalopram, sertra-
line, amitriptyline, venlafaxine, bupropion, citalopram, mirtazap-
ine, ﬂuoxetine, and ﬂuvoxamine), 8 were taking benzodiazepines
(clonazepam, lorazepam, temazepam,andoxazepam), and 15were
taking antipsychotics (quetiapine, ziprasidone, olanzapine, and
risperidone). Of the 29 patients in the study, 15 were taking a com-
bination of at least two different medications, and the remaining
14 were only taking one medication.
TREATMENTS
Patients received either ECT or rTMS as a part of their clinical
care recommended by a physician. Both treatments were admin-
istered as per hospital protocol and under instructions of the
treating psychiatrist. ECT was administered over 12 sessions, last-
ing approximately 4 weeks, with patients receiving an average of
3 sessions per week. rTMS was administered over 10 consecutive
daily sessions, lasting approximately 2 weeks. Prior to the start
of rTMS treatment, individual motor threshold (MT) on motor
cortex was determined following international standard proto-
col (Rossini et al., 1994). The stimulus intensity was set to 80%
of the patient’s MT intensity, with 10 Hz stimulation of the left
dorsolateral prefrontal cortex (DLPFC).
CLINICAL ASSESSMENTS
Patients were assessed at two time points: baseline (7 days before
treatment) and 7 days after completing ECT or rTMS treatment.
Each clinical assessment consisted of the Hamilton Depression
Rating Scale (HDRS).
SERUM BDNF DETERMINATION
Venous blood samples were collected 7 days prior to treatment
and 7 days after treatment completion. Samples were collected in
anticoagulant-free tubes. Serum samples were transported on ice
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and allowed to sit at room temperature for 30 min before sepa-
ration of the serum by centrifugation. Blood samples were cen-
trifuged at 3000 rpm for 15 min at 4˚C; serum was drawn off and
frozen at −20˚C until needed. Serum BDNF levels were measured
by a sandwich ELSIA method using the BDNF Emax ImmunoAs-
say System (Promega, 2009). The manufacturer’s instructions were
followed.
STATISTICAL ANALYSIS
Statistical analysis of data was done on SPSS 18.0 for PC (SPSS
Inc, Chicago, IL, usa). Two-sided normal distribution paired t -test
analysis with a signiﬁcance of 0.05 was conducted to compare pre-
and post-treatment measures. Bivariate correlations were assessed
using Pearson’s coefﬁcient. A one-way ANOVA with a signiﬁcance
of 0.05 was used to analyze pre-treatment variance in clinical
measures and BDNF levels within the study population.
RESULTS
A repeated measures ANOVA with medication as a covariate
was conducted to determine if varying medications through-
out the duration of the study had a possible confounding
effect on patients’ HDRS score and BDNF level outcomes. Non-
signiﬁcant results were found for both the HDRS score outcomes,
F(1,20)= 1.866, p = 0.187, as well as the BDNF level outcomes,
F(1,20)= 1.783, p = 0.197.
ELECTROCONVULSIVE THERAPY
Baseline BDNF concentrations or HDRS scores did not signiﬁ-
cantly differ between patients. Mean (±SE) baseline serum BDNF
concentration was 9.95 ng/ml (±1.94) and mean post-treatment
concentration was 12.29 ng/ml (±1.05). There was no signiﬁcant
difference between pre- and post-treatment serum BDNF levels
(t =−1.615, df = 10, p = 0.137; Figure 1). Illness severity signif-
icantly decreased following ECT (t = 3.955, df = 10, p = 0.003).
Mean (±SE) pre-treatment HDRS score was 23.73 (±1.43) and
mean post-treatment HDRS score was 13.27 (±1.90; Figure 2).
BDNF concentration was not signiﬁcantly correlated with HDRS
score following ECT (r =−0.133, p = 0.697).
REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
Baseline BDNF concentrations or HDRS scores did not signiﬁ-
cantly differ between patients. Mean (±SE) baseline serum BDNF
concentration was 10.05 ng/ml (±1.21) and mean post-treatment
concentration was 8.90 ng/ml (±1.02). There was no signiﬁcant
difference between pre- and post-treatment serum BDNF levels
(t = 1.111, df = 17, p = 0.282; Figure 3). Illness severity signiﬁ-
cantly decreased following rTMS (t = 5.645, df = 17, p< 0.001).
Mean (±SE) pre-treatment HDRS score was 23.22 (±1.15) and
mean post-treatment HDRS score was 15.11 (±1.74; Figure 4).
BDNF concentration was not signiﬁcantly correlated with HDRS
score following rTMS (r = 0.374, p = 0.126).
FIGURE 1 | Change in serum brain-derived neurotrophic factor (BDNF)
concentration from pre- to post-treatment in patients with major
depressive disorder treated with electroconvulsive therapy (ECT). Serum
BDNF was determined 1week prior to and 1week following ECT. There was
no signiﬁcant difference between pre- and post-treatment BDNF levels
(p =0.137). Values are mean±SE.
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FIGURE 2 | Change in Hamilton Depression Rating Scale (HDRS)
score from pre- to post-treatment in patients with major
depressive disorder treated with electroconvulsive therapy (ECT).
HDRS scores were determined 1week prior to and 1week following
ECT. HDRS scores signiﬁcantly decreased following ECT (p =0.003).
Values are mean±SE.
DISCUSSION
Neither ECT nor rTMS altered serum BDNF levels of patients
with MDD. Depression severity signiﬁcantly decreased following
both ECT and rTMS. The change in serum BDNF levels was not
correlated with the change in illness severity.
Several studies have examined the effect of ECT on serum
BDNF levels in patients with MDD. Our results were consistent
with those of two recent studies that also found that ECT does not
alter serum BDNF levels, despite decreasing depression severity
(Fernandes et al., 2009; Gronli et al., 2009). This suggests that ECT
may not share a similar mechanism of action as antidepressants
in improving illness severity in patients with treatment-resistant
depression.
However, the results of this study conﬂict with other studies
investigating the effect of ECT on serum BDNF levels. While the
current study shows that ECT did not alter BDNF levels, others
have reported an increase in serum BDNF levels following ECT
in patients with MDD (Marano et al., 2007). However, the time-
point at which post-treatment BDNF levels are measured is not
consistent across previous studies. Serum BDNF levels have been
measured during treatment (Marano et al., 2007), 5 weeks after the
start of ECT (Okamoto et al., 2008), as well as 1 week (Piccini et al.,
2009), 2 weeks (Hu et al., 2010), or 1 month (Bocchio-Chiavetto
et al., 2006) after treatment completion. Therefore, while ECT
may increase BDNF levels, it remains unclear as to when this
increase occurs. In this study, BDNF was measured 1 week after
treatment completion. Our non-signiﬁcant ﬁndings conﬂict with
those of Piccini et al. (2009) who found that serum BDNF lev-
els are increased 1 week after the completion of ECT. In contrast,
Bocchio-Chiavetto et al. (2006) found that BDNF levels were not
altered 1 week after ECT, however BDNF levels increased 1 month
after treatment compared to pre-treatment levels. These results
togethermay suggest that there is individual variation in the length
of time required before neuronal changes can be observed. It is
possible that changes in BDNF levels did occur in patients in this
study, however it was too early to observe these changes 1 week
after treatment completion. More time may have been needed to
observe a signiﬁcant increase in serum BDNF levels from baseline
levels.
Few studies have investigated the effect of rTMS on serum
BDNF levels in patients with MDD. Contrary to our results,
rTMS has been reported to increase BDNF levels in drug-resistant
depressed patients (Yukimasa et al., 2006; Zanardini et al., 2006).
However, our ﬁndings agree with those of Lang et al. (2006) who
also found that rTMS does not alter BDNF levels. As the results
of this study add to the inconsistency of research ﬁndings in this
area, the effect of rTMSonBDNF levels in patients with depression
remains to be established.
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FIGURE 3 | Change in serum brain-derived neurotrophic factor (BDNF)
concentration from pre- to post-treatment in patients with major
depressive disorder treated with repetitive transcranial magnetic
stimulation (rTMS). Serum BDNF was determined 1week prior to and
1week following rTMS. There was no signiﬁcant difference between pre- and
post-treatment BDNF levels (p =0.282). Values are mean±SE.
The main limitation in this study is its small sample size. It
is possible that a signiﬁcant increase in serum BDNF concentra-
tions following ECT or rTMS treatment would be observed in
a larger patient population. Furthermore, the patients are het-
erogeneous regarding the different types of medications they
were taking throughout the duration of the study. Although
it was found that patients’ medications in this study did not
signiﬁcantly affect the outcome of the results at time one or
time two, different antidepressant medication may have vary-
ing effects on BDNF concentrations. Therefore the variation in
medication taken by participants may have impeded our abil-
ity to detect an increase in BDNF levels. Finally, future studies
should measure BDNF levels at different time points following
treatment completion to report the length of time needed to
observe an increase in concentration, if in fact, BDNF levels are
augmented.
A further limitation in this study is the measurement of only
serum BDNF levels. As it is possible that serum and cerebrospinal
ﬂuid BDNF concentrations may not be correlated (Laske et al.,
2007), this study could be strengthened by measuring both serum
and CSF BDNF levels. Parallel changes in BDNF levels in serum
and CSF could indicate that serum BDNF reﬂects brain changes
in BDNF following ECT and rTMS in patients with depression.
A major concern is whether or not BDNF levels measured in the
blood reﬂect BDNF levels in the brain. Serum BDNF and whole
blood BDNF levels have been positively correlated with brain tis-
sue BDNF in rats (Karege et al., 2002b; Sartorius et al., 2009; Klein
et al., 2010) and plasma BDNF has been positively correlated with
hippocampal BDNF in pigs (Klein et al., 2010). However, whole
blood and serum BDNF levels were negatively correlated with
hippocampal BDNF levels in a genetic rat model of depression
(Elfving et al., 2010). To our knowledge, no studies have inves-
tigated this relationship in humans. It remains to be determined
whether BDNF concentrations in human brain tissue are reﬂected
in plasma and serum levels.
Furthermore, Karege et al. (2005) have suggested that changes
in serum BDNF levels may not be due to changes in blood BDNF
concentrations themselves, but rather to changes in the release
mechanisms of BDNF from platelets (Karege et al., 2005). Ninety-
nine percent of blood BDNF is thought to be stored and released
by platelets, which are thought to sequester BDNF as opposed to
synthesizing it (Karege et al., 2002b). Therefore, it is possible that
platelets sequestered BDNF and were responsible for the increases
in plasma BDNF following ECT and rTMS observed in previous
studies, rather than an increase in BDNF synthesis. Serum BDNF
measurementsmay not have accurately detected the true change in
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FIGURE 4 | Change in mean Hamilton Depression Rating Scale (HDRS)
score from pre- to post-treatment in patients with major depressive
disorder treated with repetitive transcranial magnetic stimulation
(rTMS). HDRS scores were determined 1week prior to and 1week following
rTMS. HDRS scores signiﬁcantly decreased following rTMS (p<0.001).
Values are mean±SE.
BDNF concentration, leading to a misconceived increase in BDNF
levels. Therefore, it is possible that ECT and rTMS do not in fact
alter serum BDNF levels in patients with MDD.
Our ﬁndings suggest that ECT and rTMS do not improve
depression severity by altering serum BDNF levels. Patients in
this study population were severely depressed and had undergone
several trials of antidepressant treatments. As antidepressants are
known to increase BDNF levels in patients with depression, it is
possible that changes in serumBDNF concentrations occurred fol-
lowing previous pharmacological treatments and prior to the start
of ECTor rTMS treatment in this study (Shimizu et al., 2003). ECT
or rTMS may not further increase serum BDNF concentrations in
patients who have received prior antidepressant treatment. This
suggests that an increase in serum BDNF levels may occur before
clinical improvement.
CONCLUSION
Neither ECT nor rTMS altered BDNF levels in patients with drug-
resistant MDD, despite improving depression severity. This pilot
study suggests that ECT and rTMS may not share a similar mech-
anism of action as antidepressants in improving illness severity in
patients with treatment-resistant depression. The role of serum
BDNF concentration as a biomarker for the treatment of MDD
remains to be investigated.
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